Astellas Licenses 4D’s Viral Vector In Gene Therapy Push In Rare Ophthalmic Disease
Pays $20m Upfront
Under a broader push for strategic partnerships, the Japanese firm will use 4D’s tech to develop at least one intravitreal gene therapy for a rare eye disease as it emerges undeterred by previous challenges with the modality.
